LGD-6972

• Description :

  LGD-6972 is a selective and orally active glucagon receptor antagonist. LGD-6972 has the potential for type 2 diabetes research[1].

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  GCGR

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein

• Applications :

  Metabolism-sugar/lipid metabolism

• Field of Research :

  Metabolic Disease

• Assay Protocol :

  https://www.medchemexpress.com/LGD-6972.html

• Purity :

  98.0

• Solubility :

  DMSO : 125 mg/mL (ultrasonic)

• Smiles :

  O=C(NCCS(=O)(O)=O)C1=CC=C(C[C@H](C2=CC=C(C3=CC=C(C(C)(C)C)C=C3)C=C2)C(NC4=CC=C(C5=C(C)C=C(C)C=C5C)C=C4)=O)C=C1

• Molecular Formula :

  C43H46N2O5S

• Molecular Weight :

  702.90

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Vajda EG, et al. Pharmacokinetics and pharmacodynamics of single and multiple doses of the glucagon receptor antagonist LGD-6972 in healthy subjects and subjects with type 2 diabetes mellitus. Diabetes Obes Metab. 2017 Jan;19 (1) :24-32.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 2

• CAS Number :

  [1207989-09-0]